Witamina D – składnik o wielostronnym działaniu

Joanna J. Sajkowska-Kozielewicz, Katarzyna Paradowska

DOI: http://dx.doi.org/10.12775/HERB.2016.003

Abstrakt


Biologicznie czynna forma witaminy D, czyli 1,25-dwuhydroksywitamina D3, przez lata była uważana jedynie za czynnik zapewniający odpowiedni rozwój układu kostnego i stosowana w profilaktyce zachorowań na krzywicę. Dziś coraz więcej badań wskazuje, że jest to związek mający wpływ na ponad 200 genów i większość narządów ludzkiego organizmu. Termin witamina D odnosi się zarówno do witaminy (substancja egzogenna dostarczana z zewnątrz wraz z pożywieniem), jak również prohormonu (związek endogenny produkowany w skórze pod wpływem promieni słonecznych i później przekształcanego w aktywną postać). Obecnie witamina D nie jest postrzegana wyłącznie jako czynnik zapobiegający rozwojowi krzywicy i osteoporozy. Zwiększa się liczba badań pokazujących jej udział w prawidłowej pracy układu sercowo-naczyniowego, profilaktyce cukrzycy oraz chorób nowotworowych, a także jej wpływu podczas terapii reumatoidalnego zapalenia stawów (RZS), zwyrodnienia plamki żółtej (AMD) czy łuszczycy. Celem artykułu jest przedstawienie wielokierunkowego działania witaminy D.

Słowa kluczowe


witamina D; historia; klasyczne działanie; nieklasyczne działanie

Pełny tekst:

PDF

Bibliografia


Norman, A.W., History of Vitamin D, University of California, 2011.

Sajkowska, J.J., Paradowska K., Wielokierunkowe działanie witaminy D, Biul. Wydz. Farm. WUM 2014, 1, s.1–6.

Hayes C.E., Nashold F.E., Spach K.M., Pedersen L.B., The immunological functions of the vitamin D endocrine system, Celluar and Molecular Biology (Noisy-le-grand), 2003, 49(2), s. 277–300.

Karczmarewicz E., Łukaszkiewicz J., Lorenz R., Vitamin D – metabolism, action, re-quirements and treatment strategies, Standardy Medyczne 2007, 4, s. 137–142.

Dawodu A., Tsang R., Maternal vitamin D status: effect on milk vitamin D content and vitamin D status of breastfeeding infants, Advances Nutrition, 2012, 3(3), s. 353–361.

Płudowski P., Karczmarewicz E., Chlebna-Sokół D., Czech-Kowalska J., Dębski R., Dobrzańska A., Franek E., Głuszko P., Konstantynowicz J., Książyk J.B., Księżopols-ka-Orłowska K., Lewiński A., Litwin M., Lorenc R.S., Łukaszkiewicz J., Marcinows-ka-Suchowierska E., Milewicz A., Misiorowski W., Nowicki M., Rozentryt P., Socha P., Solnica B., Szalecki M., Tałałaj M., Żmijewski M.A., Witamina D: Rekomendacje dawkowania w populacji osób zdrowych oraz w grupach ryzyka deficytów – wyty-czne dla Europy Środkowej 2013 r., Standardy Medyczne, 2013, 10, s. 573–578.

Holick M.F., Resurrection of vitamin D deficiency and rickets, Journal of Clinical In-vestigation, 2006, 116(8), s. 2062–2072.

Stumpf W.E., Sar M., Reid F.A., Tanaka Y., DeLuca H.F., Target cells for 1,25-dihy-droxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid, Science, 1979, 206(4423), s. 1188–1190.

Grant W.B., An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation, Cancer, 2002, 94(6), s.1867–1875.

Cyganek K., Sieradzki J., Występowanie cech zespołu metabolicznego u otyłych chorych, Diabetologia Praktyczna, 2004, 5(3), s. 123–129.

Komperda J., Żurkowska J., Czapka M., Szczepańska M., Pierzak-Sominka J., Zespół met-aboliczny – przegląd piśmiennictwa, Problemy Nauk Stosowanych, 2014, 2, s. 149–156.

Botella-Carretero J.I., Alvarez-Blasco F., Villafruela J.J., Balsa J.A., Vazquez C., Esco-bar-Morreale H.F., Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity, Clinical Nutrition, 2007, 26(5), s. 573–580.

Ford E.S., Ajani U.A., McGuire L.C., Liu S., Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults, Diabetes Care, 2005, 28(5), s.1228–1230.

Wortsman J., Matsuoka L.Y., Chen T.C., Lu Z., Holick M.F., Decreased bioavailability of vitamin D in obesity, American Journal of Clinical Nutrition, 2000, 72(3), s. 690–693.

Liu S., Song Y., Ford E.S., Manson J.E., Buring J.E., Ridker P.M., Dietary calcium, vi-tamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women, Diabetes Care, 2005, 28(12), s. 2926–2932.

Gagnon C., Lu Z.X., Magliano D.J., Dunstan D.W., Shaw J.E., Zimmet P.Z., Sikaris K., Ebeling P.R., Daly R.M., Low serum 25-hydroxyvitamin D is associated with in-creased risk of the development of the metabolic syndrome at five years: results from a national, population-based prospective study (The Australian Diabetes, Obesity and Lifestyle Study: AusDiab), Journal of Clinical Endocrinology and Metabolism, 2012, 97(6), s. 1953–1961.

Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M., Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study, Lancet, 2001, 358(9292), s. 1500–1503.

Sørensen I.M., Joner G., Jenum P.A., Eskild A., Torjesen P.A., Stene L.C., Maternal serum levels of 25-hydroxy-vitamin D during pregnancy and risk of type 1 diabetes in the offspring, Diabetes, 2012, 61(1), s. 175–178.

Afzal S., Bojesen S.E., Nordestgaard B.G., Low 25-hydroxyvitamin D and risk of type 2 diabetes: a prospective cohort study and metaanalysis, Clinical Chemistry, 2013, 59(2), s. 381–391.

Thomas G.N., Hartaigh B., Bosch J.A., Pilz S.,Loerbroks A., Kleber M.E., Fischer J.E., Grammer T.B., Böhm B.O., März W., Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Lud-wigshafen Risk and Cardiovascular Health (LURIC) Study, Diabetes Care, 2012, 35(5), s. 1158–1164.

Gröber U., Spitz J., Reichrath J., Kisters K., Holick M.F., Vitamin D: Update 2013: From rickets prophylaxis to general preventive healthcare, Dermatoendocrinol, 2013, 5(3), s. 331–347.

Talaei A., Mohamadi M., Adgi Z., The effect of vitamin D on insulin resistance in pa-tients with type 2 diabetes, Diabetology and Metabolic Syndrome, 2013, 5(1), s. 8–13.

Kaitin K.I., Milne C.P., Schizofrenia koncernów, Świat Nauki, 2011, 241(9), s. 18–20.

Gezen-Ak, D., Yilmazer S., Dursun E., Why vitamin D in Alzheimer’s disease? The hypothesis, Journal of Alzheimers Disease, 2014, 40(2), s. 257–269.

Annweiler C., Schott A.M., Allali G., Bridenbaugh S.A., Kressig R.W., Allain P., Herrmann F.R., Beauchet O., Dietary intake of vitamin D and cognition in older women: a large population-based study, Neurology, 2010, 75(20), s. 1810–1816.

Lopes da Silva S., Vellas B., Elemans S., Luchsinger J., Kamphuis P., Yaffe K., Sijben J., Groenendijk M., Stijnen T., Plasma nutrient status of patients with Alzheimer’s disease: Systematic review and meta-analysis, Alzheimers and Dementia, 2014, 10(4), s. 485–502.

Wilkins C.H., Sheline Y.I., Roe C.M., Birge S.J., Morris J.C., Vitamin D deficiency is as-sociated with low mood and worse cognitive performance in older adults, American Journal of Geriatric Psychiatry, 2006, 14, s. 1032–1040.

Vieth R., Kimball S., Hu A., Walfish P.G., Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients, Nutrition Journal, 2004, 3, s. 8–18.

Sato Y., Iwamoto J., Honda Y., Amelioration of osteoporosis and hypovitaminosis D by sunlight exposure in Parkinson’s disease, Parkinsonism and Related Disorders, 2011, 17(1), s. 22–26.

Kfoczyńska M., Kucharska A., Sińska B., Rola witaminy D w stwardnieniu rozsianym, Postępy Higieny i Medycyny Doświadczalnej, 2015, 69, s. 440–446.

Holick M.F., The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action, Molecular Aspects of Medicine, 2008, 29(6), s. 361–368.

Anderson J.L., May H.T., Horne B.D., Bair T.L., Hall N.L., Carlquist J.F., Lappé D.L., Muhlestein J.B., Relation of vitamin D deficiency to cardiovascular risk factors, dis-ease status, and incident events in a general healthcare population, American Journal of Cardiology, 2010, 106(7), s. 963–968.

Sun Q., Pan A., Hu F.B., Manson J.E., Rexrode K.M., 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis, Stroke, 2012, 43(6), s.1470–1477.

Schöttker B., Haug U., Schomburg L., Köhrle J., Perna L., Müller H., Holleczek B., Brenner H., Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study, American Journal of Clinical Nutrition, 2013, 97(4), s. 782–793.

Witham, M.D., Nadir, M.A., Struthers, A.D., Effect of vitamin D on blood pressure: a sys-tematic review and meta-analysis, Journal of Hypertension, 2009, 27(10), s. 1948–1954.

Forman J.P., Scott J.B., Ng K., Drake B.D., Gonzalez Suarez E., Douglas L. Hayden D.L., Bennett G.G., Chandler P.D., Hollis B.W., Emmons K.M., Giovannucci E.L., Fuchs C.S., Chan A.T., Effect of vitamin D supplementation on blood pressure in blacks, Hypertension, 2013, 61(4), s. 779–785.

Williams C., On the use and administration of cod-liver oil in pulmonary consump-tion, Journal of Medicine, 1849, 1, s. 1–18.

Ginde A.A., Mansbach J.M., Camargo C.A Jr., Association between serum 25-hy-droxyvitamin D level and upper respiratory tract infection in the Third Nation-al Health and Nutrition Examination Survey, Archives of Internal Medicine, 2009, 169(4), s. 384–390.

Urashima M., Segawa T., Okazaki M., Kurihara M., Wada Y., Ida H., Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren, American Journal of Clinical Nutrition, 2010, 91(5), s.1255–1260.

Bischoff-Ferrari H.A., Dietrich T., Orav E.J., Dawson-Hughes B., Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults, American Journal of Medicine, 2004, 116(9), s. 634–639.

Visser M., Deeg D.J.H., Puts M.T.E., Seidell J.C., Paul Lips P., Low serum concentra-tions of 25-hydroxyvitamin D in older persons and the risk of nursing home admis-sion, American Journal Clinical Nutrition, 2006, 84(3), s. 616–622.

Yüksel R.N., Altunsoy N., Tikir B., Külük M.C., Unal K., Goka S., Aydemir C., Goka E., Correlation between total vitamin D levels and psychotic psychopathology in patients with schizophrenia: therapeutic implications for add-on vitamin D augmentation, Therapeutic Advances in Psychopharmacology, 2014, 4(6), s. 268–275.

Gowda, U., Gumbie M.P., Smith B., Renzaho A., Vitamin D supplementation to re-duce depression in adults: meta-analysis of randomized controlled trials, Nutrition, 2015, 31(3), s. 421–429.

Józefowicz, O., Rabe-Jabłońska J., Woźniacka A., Strzelecki D., Analysis of vitamin D status in major depression, Journal of Psychiatric Practice, 2014, 20(5), s. 329–337.

Millen A.M., Meyers K.J., Liu Z., Engelman C.D., Wallace R.B., LeBlanc E.S., Tinker L.F., Iyengar S.K., Robinson J., Sarto G.E., Mares J.A., Association between vitamin D status and age-related mascular degeneration by genetic risk, JAMA Ophthalmology, 2015, 133(10), s. 1171–1179.

Parekh N., Chappell R.J., Millen A.E, Albert D.M., Julie A. Mares J.A., Association be-tween vitamin D and age-related macular degeneration in the Third National Health and Nutrition Examination Survey, 1988 through 1994, JAMA Ophthalmology, 2007, 125(5), s. 661–669.

Aoki A., Inoue M., Nguyen E., Obata R., Kadonosono K., Shinkai S., Hashimoto H., Sasaki S., Yanagi Y., Dietary n-3 Fatty Acid, alpha-Tocopherol, Zinc, vitamin D, vita-min C, and beta-carotene are Associated with Age-Related Macular Degeneration in Japan, Scientic Reports, 2016, 6, s. 20723–20730.

Merlino L.A., Curtis J., Mikuls T.R., Cerhan J.R., Criswell L.A., Saag K.G., Vitamin D intake is inversely assioted with rheumatoid arthritis: results from the Iowa Women’s Health Study, Arthritis and Rheumatology, 2004, 50(1), s. 72–77.

Nielen M.M.J., van Schaardenburg D., Lems W.F., van de Stadt R.J., de Koning M.H.M.T., Reesink H.W., Habibuw M.R., van der Horst-Bruinsma I.E., Twisk J.W.R., Dijkmans B.A.C., Vitamin D deficiency does not increase the risk of rheumatoid ar-thritis: comment on the article by Merlino et al, Arthritis and Rheumatology, 2006, 54(11), s. 3719–3720.

Costenbader K.H., Feskanich D., Holmes M, Karlson ME.W., Benito-Garcia E., Vita-min D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women, Ann Rheum Dis, 2008, 67(4), s. 530–535.

Pappa H.M., Gordon C.M., Vitamin D status in children and young adults with in-flammatory bowel disease, Pediatric, 2006, 118, s. 1950–1961.

Gokhale R., Favus M.J., Bone mineral density assessment in children with inflamma-tory bowel disease, Gastroenterology, 1998,114, s. 902–911.

Pappa H.M., Gordon C.M., Report on Vitamin D status in adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease, In-flammatory Bowel Diseases, 2006,12, s. 1162–1174.

Holick M.F., Clinical efficacy of 1, 25-dihydroxyvitamin D3 and its analogues in the treatment of psoriasis, Retinoids, 1998, 14, s. 12–17.

Perez A., Chen T.C., Turner A., Raab R., Bhawan J., Pochi P., Holick M.F., Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis, British Journal Dermatology, 1996, 134(2), s. 238–246.

Kozielewicz P., Grafton G., Kutner A., Curnow S.J., Gordon J., Barnes N.M., Novel vitamin D analogues; cytotoxic and anti-proliferative activity against a diffuse large B-cell lymphoma cell line and B-cells from healthy donors, Journal of Steroid Bio-chemistry and Molecular Biology, 2015.

Leyssens C., Verlinden L., Verstuyf A., The future of vitamin D analogs, Frontiers in Physiology, 2014, 122(5), s. 177–194.

Snijder M.B., van Dam R.M., Visser M., Deeg D.J., Dekker J.M., Bouter L.M., Seidell J.C., Lips P., Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women, Journal of Clinical Endocrinolo-gy and Metabolism, 2005, 90(7), s. 4119–4123.

Grant W.B., Schuitemaker G.E., Health benefits of higher serum 25-hydroxyvitamin D levels in The Netherlands, Journal of Steroid Biochemistry and Molecular Biology, 2010, 121(1–2), s. 456–458.


Refbacks

  • There are currently no refbacks.

Partnerzy platformy czasopism